Overview

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2023-04-01

Target enrollment:

Participant gender:

Summary

This is an open label, multi-institutional, single arm Phase II trial. All patients will be treated with Carboplatin, Paclitaxel, Durvalumab and Radiation. All patients with non-PD after induction therapy who remain surgical candidates will undergo surgical resection 4-12 weeks following induction therapy. After surgical resection, all patients who remain eligible will be treated with adjuvant Durvalumab every 4 weeks for 6 cycles beginning 4-12 weeks after surgical resection.

Phase:

Phase 2

Details

Lead Sponsor:

Greg Durm, MD

Collaborators:

AstraZeneca
Indiana University School of Medicine

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Carboplatin
Durvalumab
Paclitaxel